PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31044647-2	2019	METHODS: [89Zr]Zr-DFO-PD-L1 monoclonal antibody (mAb) was synthesized using avelumab conjugated to desferrioxamine.	Deferoxamine	18-21	CD274 molecule	Homo sapiens	22-27	
31044647-2	2019	METHODS: [89Zr]Zr-DFO-PD-L1 monoclonal antibody (mAb) was synthesized using avelumab conjugated to desferrioxamine.	Deferoxamine	99-114	CD274 molecule	Homo sapiens	22-27	
31044647-5	2019	RESULTS: [89Zr]Zr-DFO-PD-L1 mAb exhibited high affinity (Kd ~ 0.3 nM) and detected moderate PD-L1 expression levels in MDA-MB231 cells.	Deferoxamine	18-21	CD274 molecule	Homo sapiens	22-27	
31044647-5	2019	RESULTS: [89Zr]Zr-DFO-PD-L1 mAb exhibited high affinity (Kd ~ 0.3 nM) and detected moderate PD-L1 expression levels in MDA-MB231 cells.	Deferoxamine	18-21	CD274 molecule	Homo sapiens	92-97	
31044647-6	2019	The spleen and lymph nodes exhibited the highest [89Zr]Zr-DFO-PD-L1 mAb uptakes in all time points, while MDA-MB231 tumor uptakes were lower but highly retained.	Deferoxamine	58-61	CD274 molecule	Homo sapiens	62-67	
31044647-7	2019	In the unlabeled avelumab dose escalation studies, spleen tissue-muscle ratios decreased in a dose-dependent manner indicating specific [89Zr]Zr-DFO-PD-L1 mAb binding to PD-L1.	Deferoxamine	145-148	CD274 molecule	Homo sapiens	149-154	
31044647-7	2019	In the unlabeled avelumab dose escalation studies, spleen tissue-muscle ratios decreased in a dose-dependent manner indicating specific [89Zr]Zr-DFO-PD-L1 mAb binding to PD-L1.	Deferoxamine	145-148	CD274 molecule	Homo sapiens	170-175	
31044647-9	2019	CONCLUSIONS: [89Zr]Zr-DFO-PD-L1 mAb exhibited specific and high affinity for PD-L1 in vitro and had target tissue uptakes correlating with PD-L1 expression levels in vivo.	Deferoxamine	22-25	CD274 molecule	Homo sapiens	26-31	
31044647-9	2019	CONCLUSIONS: [89Zr]Zr-DFO-PD-L1 mAb exhibited specific and high affinity for PD-L1 in vitro and had target tissue uptakes correlating with PD-L1 expression levels in vivo.	Deferoxamine	22-25	CD274 molecule	Homo sapiens	77-82	
31044647-9	2019	CONCLUSIONS: [89Zr]Zr-DFO-PD-L1 mAb exhibited specific and high affinity for PD-L1 in vitro and had target tissue uptakes correlating with PD-L1 expression levels in vivo.	Deferoxamine	22-25	CD274 molecule	Homo sapiens	77-82	
31044647-10	2019	[89Zr]Zr-DFO-PD-L1 mAb uptake in PD-L1+tumors increased with escalating doses of avelumab.	Deferoxamine	9-12	CD274 molecule	Homo sapiens	13-18	
35512998-1	2022	Background: In the PINCH study we performed 89Zr-DFO-durvalumab (anti-PD-L1) PET/CT in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) prior to monotherapy durvalumab treatment.	Deferoxamine	49-52	CD274 molecule	Homo sapiens	70-75	
35512998-3	2022	Secondary aims were to correlate 89Zr-DFO-durvalumab uptake to tumor PD-L1 expression, 18F-FDG uptake, and treatment response of individual lesions.	Deferoxamine	38-41	CD274 molecule	Homo sapiens	69-74	
34119742-9	2021	CONCLUSION: Our data demonstrates that (89Zr)Zr-DFO-NCS-anti-PD-L1-B11 exhibits excellent imaging properties for the assessment PD-L1 expression.	Deferoxamine	48-51	CD274 molecule	Homo sapiens	61-66	
34119742-9	2021	CONCLUSION: Our data demonstrates that (89Zr)Zr-DFO-NCS-anti-PD-L1-B11 exhibits excellent imaging properties for the assessment PD-L1 expression.	Deferoxamine	48-51	CD274 molecule	Homo sapiens	128-133